Advertisement

Hellenic Journal of Surgery

, Volume 90, Issue 1, pp 27–32 | Cite as

Surgical Considerations in Subclinical Cushing’s Syndrome. When is it Time to Operate?

  • Alexander M. Nixon
  • C Aggeli
  • C Tserkezis
  • GN Zografos
Original Article
  • 7 Downloads

Abstract

Subclinical Cushing’s syndrome (SCS) is a disorder characterized by autonomous cortisol secretion and the presence of an adrenal incidentaloma, in the absence of clinical features of Cushing’s syndrome. SCS is of special interest because it has been associated with several disorders, such as atherosclerosis and arterial hypertension. Despite decades of research, SCS continues to generate controversy regarding its diagnosis and subsequent management. Several issues remain to be resolved. A universal agreement on the hormonal diagnosis of the syndrome remains elusive. Autonomous cortisol secretion has been ill defined and several definitions have been offered. The heterogeneity in diagnostic criteria creates heterogeneity in studies evaluating optimal management. Minimally invasive adrenalectomy has been documented to ameliorate SCS associated disorders in certain patients. Identifying these patients should be the focus of future research on the subject. In this review we summarize current concepts regarding SCS and indications for its surgical management.

Keywords

Hypercortisolism subclinical Cushing’s syndrome adrenal surgery 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 2017;167:630–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Mannelli M, Lenders JW, Pacak K, et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012;26:507–15.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am 2000;29:43–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Torrejon S, Webb SM, Rodriguez-Espinosa J, et al. Longlasting subclinical Addison's disease. Exp Clin Endocrinol Diabetes 2007;115:530–2.CrossRefPubMedGoogle Scholar
  5. 5.
    Conzo G, Pasquali D, Colantuoni V, et al. Current concepts of pheochromocytoma. Int J Surg 2014;12:469–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Nixon AM, Provatopoulou X, Kalogera E, et al. Circulating thyroid cancer biomarkers: Current limitations and future prospects. Clin Endocrinol (Oxf) 2017;87:117–26.CrossRefGoogle Scholar
  7. 7.
    Beierwaltes WH, Sturman MF, Ryo U, et al. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med 1974;15:246–51.PubMedGoogle Scholar
  8. 8.
    Charbonnel B, Chatal JF, Ozanne P. Does the corticoadrenal adenoma with "pre-Cushing's syndrome" exist? J Nucl Med 1981;22:1059–61.PubMedGoogle Scholar
  9. 9.
    Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014;99:4462–70.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014;2:396–405.CrossRefPubMedGoogle Scholar
  11. 11.
    Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002;87:4872–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Chiodini I, Albani A, Ambrogio AG, et al. Six controversial issues on subclinical Cushing's syndrome. Endocrine 2017;56:262–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors. Eur J Endocrinol 2016;175:G1–G34.CrossRefPubMedGoogle Scholar
  14. 14.
    Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Barzon L, Scaroni C, Sonino N, et al. Risk factors and longterm follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999;84:520–6.PubMedGoogle Scholar
  16. 16.
    Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011;96:1223–36.CrossRefPubMedGoogle Scholar
  17. 17.
    Kohara K. Sarcopenic obesity in aging population: Current status and future directions for research. Endocrine 2014;45:15–25.CrossRefPubMedGoogle Scholar
  18. 18.
    NIH sta te-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 2002;19:1-25.Google Scholar
  19. 19.
    Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1526–40.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tabarin A, Bardet S, Bertherat J, et al. Exploration and management of adrenal incidentalomas. French society of endocrinology consensus. Ann Endocrinol (Paris) 2008;69:487–500.CrossRefGoogle Scholar
  21. 21.
    Zeiger MA, Thompson GB, Duh QY, et al. American association of clinical endocrinologists and american association of endocrine surgeons Medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. Endocr Pract 2009;15:450–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Piaditis GP, Kaltsas GA, Androulakis, II, et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009;71:772–8.CrossRefGoogle Scholar
  23. 23.
    Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul) 2017;32:200–18.CrossRefGoogle Scholar
  24. 24.
    Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the italian society of endocrinology. J Clin Endocrinol Metab 2000;85:637–44.Google Scholar
  25. 25.
    Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/ hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90:871–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Iacobone M, Citton M, Scarpa M, et al. Systematic review of surgical treatment of subclinical Cushing's syndrome. Br J Surg 2015;102:318–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Perysinakis I, Marakaki C, Avlonitis S, et al. Laparoscopic adrenalectomy in patients with subclinical Cushing syndrome. Surg Endosc 2013;27:2145–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Vassiliadi DA, Ntali G, Vicha E, et al. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol (Oxf) 2011;74:438–44.CrossRefGoogle Scholar
  29. 29.
    Iacobone M, Albiger N, Scaroni C, et al. The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 2008;32:882–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Zografos GN, Perysinakis I, Vassilatou E. Subclinical Cushing's syndrome: Current concepts and trends. Hormones (Athens) 2014;13:323–37.CrossRefGoogle Scholar
  31. 31.
    Stefanidis D, Goldfarb M, Kercher KW, et al. SAGES guidelines for minimally invasive treatment of adrenal pathology. Surg Endosc 2013;27:3960–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee CR, Walz MK, Park S, et al. A comparative study of the transperitoneal and posterior retroperitoneal approaches for laparoscopic adrenalectomy for adrenal tumors. Ann Surg Oncol 2012;19:2629–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Alesina PF, Hommeltenberg S, Meier B, et al. Posterior retroperitoneoscopic adrenalectomy for clinical and subclinical Cushing's syndrome. World J Surg 2010;34:1391–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Walz MK, Alesina PF, Wenger FA, et al. Posterior retroperitoneoscopic adrenalectomy—results of 560 procedures in 520 patients. Surgery 2006;140:943–8; discussion 8-50.CrossRefPubMedGoogle Scholar
  35. 35.
    Callender GG, Kennamer DL, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy. Adv Surg 2009;43:147–57.CrossRefPubMedGoogle Scholar
  36. 36.
    Lowery AJ, Seeliger B, Alesina PF, et al. Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing's syndrome in patients with bilateral adrenal disease. Langenbecks Arch Surg 2017;402:775–85.CrossRefPubMedGoogle Scholar
  37. 37.
    Hwang I, Jung SI, Yu SH, et al. Is larger tumor size a contraindication to retroperitoneal laparoscopic adrenalectomy? World J Urol 2014;32:723–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Nigri G, Rosman AS, Petrucciani N, et al. Meta-analysis of trials comparing laparoscopic transperitoneal and retroperitoneal adrenalectomy. Surgery 2013;153:111–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Conzo G, Tartaglia E, Gambardella C, et al. Minimally invasive approach for adrenal lesions: Systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications. Int J Surg 2016;28 Suppl 1:S118–23.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Surgical Society and Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Alexander M. Nixon
    • 1
  • C Aggeli
    • 1
  • C Tserkezis
    • 1
  • GN Zografos
    • 1
  1. 1.3rd Department of SurgeryAthens General Hospital, “Georgios Gennimatas”AthensGreece

Personalised recommendations